Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

AstraZeneca R&D boss Morrison leaves to head private drugmaker

June 10, 2015
Life sciences
(Reuters) – AstraZeneca’s chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group’s research operations.
 
A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States, adding there had been no disagreement with other top managers at AstraZeneca.
 
“It is not appropriate for us to confirm the name of the company but it is an exciting new opportunity for him,” she said.
 
Morrison, who joined AstraZeneca from Pfizer in 2012, has played a central role in the British drugmaker’s bid to turn around its portfolio. He also helped defend the firm’s independence in the face of a $118 billion takeover attempt by Pfizer last year.
 
Morrison will cease his current roles at the end of the week and leave AstraZeneca shortly after.
 
While the drugmaker seeks a successor, Chief Executive Pascal Soriot will take over responsibility for medicines development and Elisabeth Bjork will act as chief medical officer.
 
Soriot, who took over as CEO in October 2012, chose Morrison as one of his key drug research lieutenants, alongside Mene Pangalos, who heads early development work, and Bahija Jallal, leader of the group’s MedImmune biotech unit.
 
AstraZeneca has won plaudits for recent progress with its pipeline of experimental drugs, especially in cancer, where it is investing heavily in the hot new field of immunotherapy.
 
Still, many industry analysts remain sceptical about its ability to lift sales to $45 billion by 2023 from $26 billion last year, a target set by Soriot when the company was fighting off Pfizer’s attempted takeover last year.
 
It has suffered some setbacks, too, most recently when its partner Amgen pulled out of a psoriasis drug collaboration last month after suicidal thoughts were observed in patients taking the medicine.
 
AstraZeneca said it had not issued a formal statement about Morrison’s exit because he was not a board member. 
 
By Ben Hirschler (Editing by David Holmes)

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach